FOLFOX

Overview

FOLFOX is a combination chemotherapy regimen widely used in the treatment of colorectal cancer and, increasingly, other gastrointestinal malignancies. The name is an acronym derived from its constituent agents: FOLinic acid (leucovorin), Fluorouracil (5-FU), and OXaliplatin. The regimen works through complementary cytotoxic mechanisms: fluorouracil inhibits thymidylate synthase, thereby blocking DNA synthesis in rapidly dividing tumor cells, while leucovorin enhances fluorouracil's binding to its target enzyme, and oxaliplatin forms platinum-DNA adducts that induce apoptosis. The most commonly used formulation, mFOLFOX6 (modified FOLFOX6), involves a simplified dosing schedule of oxaliplatin and leucovorin administered intravenously on day one, followed by a 46-hour continuous infusion of fluorouracil, repeated every two weeks.

Since its clinical introduction, FOLFOX has become a foundational backbone for both adjuvant and first-line metastatic colorectal cancer treatment, and its utility continues to be explored across an expanding range of oncologic contexts. Its compatibility with targeted agents and immune checkpoint inhibitors has made it a versatile platform for combination strategies, while ongoing research continues to probe mechanisms of resistance and optimize patient selection.

Focus of Latest Publications

Recent publications reflect a broad and rapidly evolving research landscape centered on FOLFOX, spanning resistance biology, combination immunotherapy, cost-effectiveness modeling, and expanded disease indications.

Adjuvant Therapy in Colorectal Cancer

The long-term results of the JCOG0603 randomized phase II/III trial (PMID: 41564372) provided mature data on adjuvant mFOLFOX6 following hepatectomy for colorectal liver-only metastasis (CRLM). The trial demonstrated improved disease-free survival (DFS) with adjuvant mFOLFOX6 compared to hepatectomy alone, though overall survival data remained immature at the time of reporting, underscoring the ongoing challenge of translating DFS gains into survival benefit in the resected metastatic setting. Separately, the Alliance N0147 phase III trial (PMID: 41616224) examined FOLFOX-based adjuvant chemotherapy in stage III colon cancer, using a tissue-free circulating tumor DNA (ctDNA) assay to interrogate its utility as a predictive biomarker of patient outcome — positioning molecular monitoring as a future tool for refining adjuvant treatment decisions.

Combination with immunotherapy

A landmark study published in The New England Journal of Medicine (PMID: 41880612) evaluated atezolizumab combined with FOLFOX as adjuvant therapy for stage III mismatch repair-deficient (dMMR) colon cancer. As standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen, the addition of checkpoint inhibitor with atezolizumab represents a hypothesis-driven extension of FOLFOX's established role, leveraging the known immunogenicity of dMMR tumors. This study exemplifies a growing paradigm of combining FOLFOX's cytotoxic activity with immunotherapeutic synergy.

Hepatocellular Carcinoma and HAIC

FOLFOX has also been studied beyond colorectal indications. The HILL phase 2 trial (PMID: 42135293) investigated hepatic arterial infusion chemotherapy using the FOLFOX regimen (FOLFOX-HAIC) in combination with lenvatinib and the PD-L1 inhibitor durvalumab for unresectable hepatocellular carcinoma (uHCC). All patients received this triple-combination regimen as initial therapy, with the study aiming to evaluate both efficacy and safety of this multi-modal approach. This reflects the emerging use of regionally delivered FOLFOX as a scaffold for systemic targeted and immune therapies in primary liver malignancies.

BRAF-Mutant Metastatic Colorectal Cancer

A cost-effectiveness analysis from a Chinese healthcare perspective (PMID: 42185244) modeled the economic value of encorafenib plus cetuximab (EC) versus EC combined with mFOLFOX6 as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer, drawing on data from the BREAKWATER trial. This analysis highlights the health-economic dimension of incorporating mFOLFOX6 into triplet regimens for genomically defined patient subsets, with cetuximab remaining a key combinatorial partner.

Resistance Mechanisms

The role of FOLFOX resistance in colorectal cancer biology was illuminated by research into DKC1 and sphingolipid biosynthesis dysregulation (PMID: 42151151). This study demonstrated that FOLFOX-resistant patient-derived organoids — a clinically relevant preclinical model — could be resensitized via DKC1 and Wnt signaling inhibitors, suggesting that the Wnt signaling pathway contributes to resistance mechanisms and may represent a therapeutic target in patients who progress on FOLFOX-based regimens. The relationship between FOLFOX treatment response and irinotecan-based therapies was also explored in the context of pancreatic ductal adenocarcinoma (PMID: 42043185), where FOLFOX served as a comparator regimen in evaluating TOPO-1 expression and drug sensitivity prediction.

Administration and Quality of Life

A prospective observational study by the Turkish Oncology Group (PMID: 42174259) compared home-based port infusion versus hospital-based peripheral infusion in patients receiving prolonged regimens including mFOLFOX6, measuring anxiety and quality of life as primary outcomes. Additionally, the AIO/IKF ELDERLY randomized phase 2 trial (PMID: 41905242) directly evaluated FOLFOX as a first-line regimen against aflibercept plus 5-FU in older adults or frail elderly patients with metastatic colorectal cancer who were ineligible for full-dose combination regimens — addressing a clinically underserved population for whom standard FOLFOX intensity may not be appropriate.